Scroll to top

GSK

ENABLING A PHARMACEUTICAL R&D PIPELINE

CLIENT

GSK logo
REQUIREMENT
REQUIREMENT

With regards to optimising pharmaceutical research and development, GSK asked a question common to the pharmaceutical industry: How can computer modelling improve pharmaceutical research and development (R&D)?

CHALLENGE
CHALLENGE

Provide GSK with the necessary and expanded flexibility to easily define problems for optimisation in the tool, and give understandable transparent explanations of the results.

SOLUTION
SOLUTION

A transparent and easy to use model of an R&D pipeline that simulates the development and maturing of future products, against commercial demand profiles for them to provide insight into progression strategies.

How best to optimise pharmaceutical research and development
How best to optimise pharmaceutical research and development

For GSK, and the pharmaceutical industry in general, R&D is fundamental. The success of a major drug company is almost entirely dependent on its ability to discover and develop new medicines. This is why pharmaceutical R&D spending is so high – it is the second largest of all industries. In 2022, GSK spent almost £5.5 billion on R&D.

However, the traditional approach to R&D has a low success rate and is very expensive. This puts significant pressure on the industry and optimising pharmaceutical research and development is key to ensuring success.

One promising approach is to use R&D pipeline computer modelling. This type of modelling simulates the processes involved in pharmaceutical research and development, helping identify bottlenecks and inefficiencies, allowing experimentation, and providing a means to analyse performance. It can also be used to help answer what-if questions.

By using computer simulation modelling, the pharmaceutical companies can identify efficiencies and improve their R&D processes. This can lead to the discovery of new drugs more quickly and efficiently, which can improve the return on investment for drug discovery.

 

The future of simulating chemical assets
The future of simulating chemical assets

Using agent-based modeling techniques, we developed an advanced simulation environment that can predict the future of chemical assets. This means that GSK can now simulate the development of new compounds, test different R&D strategies, and see how they impact cost and ROI.

Our simulation environment for optimising pharmaceutical research and development is highly adaptable, so you can tailor it to your specific needs. You can also run a range of scenarios to see how different factors might affect the outcome. It is a powerful tool that helps make better decisions about R&D investments.

Here are some of the benefits of our simulation environment:

  • Predict the future of chemical assets with greater accuracy
  • Test different R&D strategies and see how they impact cost and ROI
  • Identify the most promising compounds to focus on
  • Reduce the risk of failure and increase your chances of success

If you're looking for a way to improve your R&D process, our decision intelligence solution is perfect. Contact us today to learn more.

Flexibility
Flexibility

We developed a method for easily and flexibly configuring attributes of entities or assets within a pharmaceutical research and development pipeline model. GSK wanted this flexible configuration capacity for any number of attributes and any number of assets. Providing this level of flexibility within a simulation while maintaining simplicity, defined the challenge.

Transparent Results
Transparent Results

Results from the simulation model inform important investment decisions. For this reason, it was unacceptable to produce a black-box model with no visibility of simulation logic and outputs without supporting information. Instead, to support a transparent decision-making process, we created a user-friendly interface that allows users to visualise the progression of products across the pipeline and to understand the business logic that has been embedded in each stage of the process.

Future Development
Future Development

Key concepts of the model are not restricted to the pharmaceutical industry. A similar approach could be applied to any industry with a R&D pipeline. For instance, in the fast moving consumer goods (FMCG) industry, many iterations of a product are tested to see how effectively they meet consumer needs – the likelihood of a product progressing from the concept stage through to market launch could be simulated with our modelling solution.

Simulation model dashboard for optimising pharmaceutical research and development

Let’s collaborate

Send us an email, to discuss a new project.

We’re a team of innovators who are excited about unique ideas and help companies to create amazing solutions.

Pharmaceuticals

Optimising GSK Research and Develpment

We use cookies to give you the best experience.